View Older Stories View More Recent Stories

Aug 24, 2020 07:00AM Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Aug 6, 2020 07:00AM Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
Aug 6, 2020 07:00AM Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
Aug 4, 2020 07:00AM Orchard Therapeutics to Present at Wedbush PacGrow Healthcare Virtual Conference
Aug 4, 2020 07:00AM Orchard Therapeutics to Present at Wedbush PacGrow Healthcare Virtual Conference
Jul 30, 2020 07:00AM Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
Jul 30, 2020 07:00AM Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
Jul 20, 2020 07:00AM Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
Jul 20, 2020 07:00AM Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
Jul 15, 2020 07:02AM Orchard Therapeutics (ORTX) Announces Global License Agreements for Stable Cell Line Technology from GSK
Jul 15, 2020 07:00AM Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK
Jul 15, 2020 07:00AM Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK
Jul 9, 2020 07:00AM Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
Jul 9, 2020 07:00AM Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
May 27, 2020 07:00AM Orchard Therapeutics to Present at Virtual Investor Conferences in June
May 27, 2020 07:00AM Orchard Therapeutics to Present at Virtual Investor Conferences in June
May 15, 2020 06:01AM Orchard Therapeutics Plc (ORTX) Highlights New Interim Data from OTL-203 Proof-of-Concept Study for MPS-I
May 15, 2020 06:00AM Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
May 15, 2020 06:00AM Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
May 7, 2020 07:00AM Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
May 7, 2020 07:00AM Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
May 1, 2020 07:00AM Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results
May 1, 2020 07:00AM Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results
Apr 29, 2020 07:00AM Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
Apr 29, 2020 07:00AM Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
Apr 27, 2020 07:04AM Orchard Therapeutics (ORTX) Reports First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)
Apr 27, 2020 07:00AM Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)
Apr 27, 2020 07:00AM Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)
Mar 31, 2020 04:11PM Orchard Therapeutics Plc (ORTX) Provides Update Related to COVID-19 Outbreak
Mar 31, 2020 04:05PM Orchard Therapeutics Outlines Business Impact of COVID-19
Mar 31, 2020 04:05PM Orchard Therapeutics Outlines Business Impact of COVID-19
Mar 18, 2020 07:00AM Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
Mar 18, 2020 07:00AM Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
Feb 27, 2020 07:00AM Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020
Feb 27, 2020 07:00AM Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020
Feb 26, 2020 07:00AM Orchard Therapeutics to Present at Investor Conferences in March
Feb 26, 2020 07:00AM Orchard Therapeutics to Present at Investor Conferences in March
Feb 20, 2020 07:00AM Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results
Feb 20, 2020 07:00AM Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results
Feb 10, 2020 07:00AM Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
Feb 10, 2020 07:00AM Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
Feb 3, 2020 07:04AM Orchard Therapeutics Plc (ORTX) Announces Steven Altschuler, M.D. to Board
Feb 3, 2020 07:00AM Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors
Feb 3, 2020 07:00AM Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors
Feb 3, 2020 07:00AM Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors
Jan 29, 2020 07:19AM Orchard Therapeutics (ORTX) Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
Jan 29, 2020 07:00AM Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
Jan 29, 2020 07:00AM Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
Jan 13, 2020 07:00AM Orchard Therapeutics Highlights 2020 Strategic Priorities
Jan 13, 2020 07:00AM Orchard Therapeutics Highlights 2020 Strategic Priorities
View More Recent Stories View Older Stories